Drug intelligence / Profile preview

ABD-003

Development stage: Preclinical
Lead developer: Abdera Therapeutics
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Likely Intravenous

Overview

ABD-003 is a therapeutic radiopharmaceutical in preclinical development by Abdera Therapeutics. It is designed as a targeted radiopharmaceutical therapy, likely leveraging Abdera’s proprietary ROVEr platform, which engineers precision radiotherapeutics for cancer. While the specific target and radioisotope payload of ABD-003 have not been disclosed publicly, it is part of Abdera's pipeline focused on delivering potent radioisotopes to selectively destroy cancer cells while minimizing systemic toxicity. The drug has not yet entered clinical trials and remains in the preclinical research phase[1].

Beyond the preview

Go deeper on ABD-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABD-003.

Explore the full profile